BACKGROUND: Gammadelta T lymphocytes are an important component of innate immunity. Previous studies have shown their role in the development of Crohn's-like colitis in mice. AIMS: The aim of this study was to measure the γδ T lymphocyte levels in Crohn's disease (CD) patients. METHODS: A prospective study of 40 patients with CD compared with 40 healthy subjects (control group) matched by age and sex was undertaken. Lennard-Jones criteria were used for the diagnosis of CD. Disease activity was measured with the Crohn's disease activity index (CDAI). New patients, patients in remission, and patients with active disease were evaluated. Lymphocytic populations of CD3+, CD4+, CD8+, CD56+, CD19+, and αβ and γδ subsets were measured in the peripheral blood of all participants. RESULTS: The levels of CD3+, CD4+, CD8+, and CD19+ lymphocytes were decreased in CD patients compared with the control group (P = 0.002, 0.049, 0.003, and 0.023, respectively). Although both γδ and αβ T lymphocytes were lower in patients with CD, γδ T subsets showed the lowest levels in CD patients (mean 0.0259 × 10(9)/l) versus healthy controls (mean 0.0769 × 10(9)/l), P < 0.001. In particular, γδ CD8+ T subsets (mean 0.0068 × 10(9)/l) had the largest difference compared to the control group (mean 0.0199 × 10(9)/l), P = 0.008. CONCLUSIONS: There is a decrease in the global lymphocyte population in the peripheral blood of patients with CD compared to healthy controls. This decrease is more evident in γδ T lymphocytes, especially γδ CD8+ T subsets. Our conclusion is that these results support the theory that a complex alteration of immune responses that affects the total numbers and function of γδ T cells is present in CD.
BACKGROUND: Gammadelta T lymphocytes are an important component of innate immunity. Previous studies have shown their role in the development of Crohn's-like colitis in mice. AIMS: The aim of this study was to measure the γδ T lymphocyte levels in Crohn's disease (CD) patients. METHODS: A prospective study of 40 patients with CD compared with 40 healthy subjects (control group) matched by age and sex was undertaken. Lennard-Jones criteria were used for the diagnosis of CD. Disease activity was measured with the Crohn's disease activity index (CDAI). New patients, patients in remission, and patients with active disease were evaluated. Lymphocytic populations of CD3+, CD4+, CD8+, CD56+, CD19+, and αβ and γδ subsets were measured in the peripheral blood of all participants. RESULTS: The levels of CD3+, CD4+, CD8+, and CD19+ lymphocytes were decreased in CDpatients compared with the control group (P = 0.002, 0.049, 0.003, and 0.023, respectively). Although both γδ and αβ T lymphocytes were lower in patients with CD, γδ T subsets showed the lowest levels in CDpatients (mean 0.0259 × 10(9)/l) versus healthy controls (mean 0.0769 × 10(9)/l), P < 0.001. In particular, γδ CD8+ T subsets (mean 0.0068 × 10(9)/l) had the largest difference compared to the control group (mean 0.0199 × 10(9)/l), P = 0.008. CONCLUSIONS: There is a decrease in the global lymphocyte population in the peripheral blood of patients with CD compared to healthy controls. This decrease is more evident in γδ T lymphocytes, especially γδ CD8+ T subsets. Our conclusion is that these results support the theory that a complex alteration of immune responses that affects the total numbers and function of γδ T cells is present in CD.
Authors: M M Kosiewicz; C C Nast; A Krishnan; J Rivera-Nieves; C A Moskaluk; S Matsumoto; K Kozaiwa; F Cominelli Journal: J Clin Invest Date: 2001-03 Impact factor: 14.808
Authors: S P L Travis; E F Stange; M Lémann; T Oresland; Y Chowers; A Forbes; G D'Haens; G Kitis; A Cortot; C Prantera; P Marteau; J-F Colombel; P Gionchetti; Y Bouhnik; E Tiret; J Kroesen; M Starlinger; N J Mortensen Journal: Gut Date: 2006-03 Impact factor: 23.059
Authors: E F Stange; S P L Travis; S Vermeire; C Beglinger; L Kupcinkas; K Geboes; A Barakauskiene; V Villanacci; A Von Herbay; B F Warren; C Gasche; H Tilg; Stefan W Schreiber; J Schölmerich; W Reinisch Journal: Gut Date: 2006-03 Impact factor: 23.059
Authors: L D McVay; B Li; R Biancaniello; M A Creighton; D Bachwich; G Lichtenstein; J L Rombeau; S R Carding Journal: Mol Med Date: 1997-03 Impact factor: 6.354
Authors: M Boirivant; M Marini; G Di Felice; A M Pronio; C Montesani; R Tersigni; W Strober Journal: Gastroenterology Date: 1999-03 Impact factor: 22.682
Authors: J Doering; B Begue; M J Lentze; F Rieux-Laucat; O Goulet; J Schmitz; N Cerf-Bensussan; F M Ruemmele Journal: Gut Date: 2004-11 Impact factor: 23.059
Authors: Ignacio Catalan-Serra; Juan Carlos Andreu-Ballester; Torunn Bruland; Arne Kristian Sandvik Journal: Dig Dis Sci Date: 2018-05-11 Impact factor: 3.199
Authors: C Benet-Campos; C Cuéllar; C García-Ballesteros; V Zamora; R Gil-Borrás; I Catalán-Serra; F López-Chuliá; J C Andreu-Ballester Journal: Dig Dis Sci Date: 2017-02-06 Impact factor: 3.199
Authors: Juan C Andreu-Ballester; Rafael Gil-Borrás; Carlos García-Ballesteros; Ignacio Catalán-Serra; Victoria Amigo; Virgina Fernández-Fígares; Carmen Cuéllar Journal: World J Gastroenterol Date: 2015-04-21 Impact factor: 5.742
Authors: T Sree Latha; Madhava C Reddy; Prasad V R Durbaka; Aparna Rachamallu; Reddanna Pallu; Dakshayani Lomada Journal: Front Immunol Date: 2014-11-10 Impact factor: 7.561
Authors: Juan C Andreu-Ballester; Carlos Garcia-Ballesteros; Victoria Amigo; Ferran Ballester; Rafael Gil-Borrás; Ignacio Catalán-Serra; Angela Magnet; Soledad Fenoy; Carmen del Aguila; Jose Ferrando-Marco; Carmen Cuéllar Journal: PLoS One Date: 2013-04-18 Impact factor: 3.240
Authors: A Galler; B C Rütgen; E Haas; A Saalmüller; R A Hirt; W Gerner; I Schwendenwein; B Richter; J G Thalhammer; N Luckschander-Zeller Journal: J Vet Intern Med Date: 2017-09-01 Impact factor: 3.333